Merck reaches an antibody drug acquisition agreement worth over 800 million dollars
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Glonghui, March 31st | According to Yicai, biopharmaceutical company Infinimmune has announced an agreement with Merck & Co. to develop multiple antibodies targeting various disease targets. The total value of this deal is expected to reach approximately $838 million. Infinimmune stated that it will use its proprietary platform to screen human immune cells and identify naturally occurring antibodies, then further develop these antibodies using AI tools. Merck & Co. will have exclusive rights to develop and commercialize the antibody drug candidates resulting from the collaboration.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Yonhap News: South Korean Court Rejects Request to Suspend Samsung's Main Union Negotiations
Cointime•2026/05/26 06:41
Asian Stocks Close Mixed, with South Korea's KOSPI Index Up 2.55%
BlockBeats•2026/05/26 06:35
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$76,884.24
-0.62%
Ethereum
ETH
$2,100.05
-0.27%
Tether USDt
USDT
$0.9989
+0.01%
BNB
BNB
$658.45
-0.31%
XRP
XRP
$1.35
-0.63%
USDC
USDC
$0.9997
-0.00%
Solana
SOL
$84.66
-1.38%
TRON
TRX
$0.3740
+2.00%
Dogecoin
DOGE
$0.1015
-1.14%
Hyperliquid
HYPE
$60.59
-2.70%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now